173 related articles for article (PubMed ID: 34008275)
1. Prostate-specific antigen density during dutasteride treatment for 1 year predicts the presence of prostate cancer in benign prostatic hyperplasia after the first negative biopsy (PREDICT study).
Inoue T; Yoshimura K; Terada N; Tsukino H; Murota T; Kinoshita H; Kamoto T; Ogawa O; Matsuda T
Int J Urol; 2021 Aug; 28(8):849-854. PubMed ID: 34008275
[TBL] [Abstract][Full Text] [Related]
2. Effect of dutasteride on the risk of prostate cancer.
Andriole GL; Bostwick DG; Brawley OW; Gomella LG; Marberger M; Montorsi F; Pettaway CA; Tammela TL; Teloken C; Tindall DJ; Somerville MC; Wilson TH; Fowler IL; Rittmaster RS;
N Engl J Med; 2010 Apr; 362(13):1192-202. PubMed ID: 20357281
[TBL] [Abstract][Full Text] [Related]
3. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia.
Andriole GL; Roehrborn C; Schulman C; Slawin KM; Somerville M; Rittmaster RS
Urology; 2004 Sep; 64(3):537-41; discussion 542-3. PubMed ID: 15351586
[TBL] [Abstract][Full Text] [Related]
4. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.
Andriole GL; Bostwick D; Brawley OW; Gomella L; Marberger M; Montorsi F; Pettaway C; Tammela TL; Teloken C; Tindall D; Freedland SJ; Somerville MC; Wilson TH; Fowler I; Castro R; Rittmaster RS;
J Urol; 2011 Jan; 185(1):126-31. PubMed ID: 21074214
[TBL] [Abstract][Full Text] [Related]
5. Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.
Roehrborn CG; Andriole GL; Wilson TH; Castro R; Rittmaster RS
Eur Urol; 2011 Feb; 59(2):244-9. PubMed ID: 21093145
[TBL] [Abstract][Full Text] [Related]
6. Effect of dutasteride on clinical progression of benign prostatic hyperplasia in asymptomatic men with enlarged prostate: a post hoc analysis of the REDUCE study.
Toren P; Margel D; Kulkarni G; Finelli A; Zlotta A; Fleshner N
BMJ; 2013 Apr; 346():f2109. PubMed ID: 23587564
[TBL] [Abstract][Full Text] [Related]
7. Dutasteride and prostate cancer.
Schröder FH; Roobol MJ
N Engl J Med; 2010 Aug; 363(8):793-4; author reply 794-5. PubMed ID: 20842789
[No Abstract] [Full Text] [Related]
8. Clinical usefulness of serum prostate specific antigen for the detection of prostate cancer is preserved in men receiving the dual 5alpha-reductase inhibitor dutasteride.
Andriole GL; Marberger M; Roehrborn CG
J Urol; 2006 May; 175(5):1657-62. PubMed ID: 16600723
[TBL] [Abstract][Full Text] [Related]
9. Dutasteride and prostate cancer.
Klotz L
N Engl J Med; 2010 Aug; 363(8):794; author reply 795-6. PubMed ID: 20842791
[No Abstract] [Full Text] [Related]
10. [Specific antigen prostatic changes during treatment with finasteride or dutasteride for benign prostatic hyperplasia].
Arena F
Minerva Urol Nefrol; 2013 Sep; 65(3):211-6. PubMed ID: 23872632
[TBL] [Abstract][Full Text] [Related]
11. [CLINICOPATHOLOGICAL STUDY OF PROSTATE BIOPSY IN PATIENTS RECEIVING DUTASTERIDE FOR BENIGN PROSTATIC HYPERPLASIA].
Endo T; Kamiya N; Yano M; Oka R; Lee FC; Utsumi T; Kamijima S; Nishimi D; Takanami M; Hiruta N; Suzuki H
Nihon Hinyokika Gakkai Zasshi; 2015 Jul; 106(3):156-62. PubMed ID: 26419072
[TBL] [Abstract][Full Text] [Related]
12. Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.
Roehrborn CG; Nickel JC; Andriole GL; Gagnier RP; Black L; Wilson TH; Rittmaster RS
Urology; 2011 Sep; 78(3):641-6. PubMed ID: 21764428
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of prostate-specific antigen (PSA) rise as a marker of prostate cancer in men treated with dutasteride: lessons from the REDUCE study.
Marberger M; Freedland SJ; Andriole GL; Emberton M; Pettaway C; Montorsi F; Teloken C; Rittmaster RS; Somerville MC; Castro R
BJU Int; 2012 Apr; 109(8):1162-9. PubMed ID: 21699645
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.
Roehrborn CG; Boyle P; Nickel JC; Hoefner K; Andriole G;
Urology; 2002 Sep; 60(3):434-41. PubMed ID: 12350480
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia.
Roehrborn CG; Marks LS; Fenter T; Freedman S; Tuttle J; Gittleman M; Morrill B; Wolford ET
Urology; 2004 Apr; 63(4):709-15. PubMed ID: 15072886
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of sexual function after dutasteride treatment in patients with once-negative prostate biopsy and benign prostate hyperplasia.
Taniguchi H; Inoue T; Kawa G; Murota T; Tsukino H; Yoshimura K; Kamoto T; Ogawa O; Matsuda T; Kinoshita H
Urologia; 2023 May; 90(2):295-300. PubMed ID: 36992564
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer gene 3 score predicts prostate biopsy outcome in men receiving dutasteride for prevention of prostate cancer: results from the REDUCE trial.
Aubin SM; Reid J; Sarno MJ; Blase A; Aussie J; Rittenhouse H; Rittmaster RS; Andriole GL; Groskopf J
Urology; 2011 Aug; 78(2):380-5. PubMed ID: 21820580
[TBL] [Abstract][Full Text] [Related]
18. [Comparison in the follow-up of two patients with persistent elevated PSA and negative prostate biopsy].
Sciarra A; Panebianco V
Urologia; 2014; 81(1):60-3. PubMed ID: 24585440
[TBL] [Abstract][Full Text] [Related]
19. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial.
Andriole G; Bostwick D; Brawley O; Gomella L; Marberger M; Tindall D; Breed S; Somerville M; Rittmaster R;
J Urol; 2004 Oct; 172(4 Pt 1):1314-7. PubMed ID: 15371831
[TBL] [Abstract][Full Text] [Related]
20. Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride.
Muller RL; Gerber L; Moreira DM; Andriole G; Hamilton RJ; Fleshner N; Parsons JK; Freedland SJ
Eur Urol; 2013 Jun; 63(6):1115-21. PubMed ID: 23541458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
